These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26046807)

  • 1. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.
    Korošec P; Žiberna K; Šilar M; Dežman M; Čelesnik Smodiš N; Rijavec M; Kopač P; Eržen R; Lalek N; Bajrović N; Košnik M; Zidarn M
    Clin Exp Allergy; 2015 Oct; 45(10):1579-89. PubMed ID: 26046807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High sensitivity of basophils predicts side-effects in venom immunotherapy.
    Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
    Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children.
    Cichocka-Jarosz E; Dorynska A; Pietrzyk JJ; Spiewak R
    Immunotherapy; 2011 Aug; 3(8):1013-7. PubMed ID: 21843104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of the Severity of Honeybee Sting Reactions and the Severity and Threshold of Systemic Adverse Events During Immunotherapy.
    Kopač P; Custovic A; Zidarn M; Šilar M; Šelb J; Bajrović N; Eržen R; Košnik M; Korošec P
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3157-3163.e5. PubMed ID: 33962066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
    J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy.
    Erdmann SM; Sachs B; Kwiecien R; Moll-Slodowy S; Sauer I; Merk HF
    Allergy; 2004 Oct; 59(10):1102-9. PubMed ID: 15355470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venom immunotherapy: clinical efficacy, safety and contraindications.
    Kosnik M; Korosec P
    Expert Rev Clin Immunol; 2015; 11(8):877-84. PubMed ID: 26018865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring honeybee venom immunotherapy in children with the basophil activation test.
    Žitnik SE; Vesel T; Avčin T; Šilar M; Košnik M; Korošec P
    Pediatr Allergy Immunol; 2012 Mar; 23(2):166-72. PubMed ID: 22136583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basophil activation can predict clinical sensitivity in patients after venom immunotherapy.
    Kucera P; Cvackova M; Hulikova K; Juzova O; Pachl J
    J Investig Allergol Clin Immunol; 2010; 20(2):110-6. PubMed ID: 20461965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy.
    Eberlein-König B; Schmidt-Leidescher C; Rakoski J; Behrendt H; Ring J
    J Investig Allergol Clin Immunol; 2006; 16(1):5-10. PubMed ID: 16599242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A; Confino-Cohen R
    Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of systemic allergic reactions during Hymenoptera venom immunotherapy buildup phase.
    Stoevesandt J; Hosp C; Kerstan A; Trautmann A
    J Dtsch Dermatol Ges; 2014 Mar; 12(3):244-55, 244-56. PubMed ID: 24580878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basophil response and the induction of a tolerance in venom immunotherapy: a long-term sting challenge study.
    Eržen R; Košnik M; Silar M; Korošec P
    Allergy; 2012 Jun; 67(6):822-30. PubMed ID: 22469017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy.
    Ebo DG; Hagendorens MM; Schuerwegh AJ; Beirens LM; Bridts CH; De Clerck LS; Stevens WJ
    Cytometry B Clin Cytom; 2007 May; 72(3):196-203. PubMed ID: 17111386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.
    Siegmund R; Vogelsang H; Machnik A; Herrmann D
    J Allergy Clin Immunol; 2000 Dec; 106(6):1190-5. PubMed ID: 11112905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
    Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
    Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of FcεRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization.
    Čelesnik Smodiš N; Šilar M; Eržen R; Rijavec M; Košnik M; Korošec P
    PLoS One; 2014; 9(4):e94762. PubMed ID: 24733549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability during build-up phase of a rush venom immunotherapy.
    Bernkopf K; Rönsch H; Spornraft-Ragaller P; Neumeister V; Bauer A
    Ann Allergy Asthma Immunol; 2016 Apr; 116(4):360-5. PubMed ID: 27055991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.